NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Corcept Therapeutics Incorporated (CORT) Stock Analysis

Corcept Therapeutics Incorporated (CORT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CORT

$111.62

−$1.18 (−1.05%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CORT with… →

CORT Key Statistics

As of Sep 4, 2026
Trading
Open
$110.59
Previous Close
$112.80
Day's Range
109.26–112.13
52-Week Range
28.66–126.38
Volume
604.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.45
Valuation
Market Cap
$12.07B
P/E Ratio
248.04
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
25.35
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.81
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
14.52
EPS (ttm)Profit attributable to each share over the last twelve months.
0.45
Financials (FY)
Revenue (FY)
$761.41M+12.79%
Net Income (FY)
$99.65M−29.43%
Profit marginThe share of revenue left as profit after all costs and taxes.
6.64%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
108.10M
1-Year Return
+60.91%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
1.08M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CORT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+220.75%
2025−30.94%
2024+55.14%
2023+59.92%
2022+2.58%
2021−24.31%
2020+116.20%
2019−9.43%
2018−26.02%
2017+148.76%
2016 (partial year)+24.53%

As of September 4, 2026.

CORT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$761.41M$99.65M13.1%
2024$675.04M$141.21M20.9%
2023$482.38M$106.14M22.0%
2022$401.86M$101.42M25.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$761.41M$748.43M$44.80M$99.65M13.1%
2024$675.04M$664.16M$136.95M$141.21M20.9%
2023$482.38M$475.89M$107.28M$106.14M22.0%
2022$401.86M$396.47M$112.63M$101.42M25.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CORT Valuation vs Biotechnology Median

Median of 656 stocks
MetricCORTBiotechnology medianvs median
P/E248.0412.5719.7x the median
P/S ratio14.5215.265% below
Profit margin6.64%0.00%6.6 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Corcept Therapeutics Incorporated (CORT) carries a market capitalisation of $12.07B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 730.

The 52-week range on file runs from $28.66 to $126.38. CORT last closed at $111.62 on September 4, 2026. That is −$1.18 (−1.05%) against the previous close. The latest close sits 289.46% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $761.41M. Against the prior fiscal year total of $675.04M, that is a change of +12.79%. The same year closed with net income of $99.65M. That is −29.43% against the prior fiscal year. The reported profit margin is 6.64%. That is 6.6 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 0.45.

Across the 4 fiscal years on file, revenue moves from $401.86M in 2022 to $761.41M in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 248.04. That is 19.7 times the Biotechnology median of 12.57. The forward P/E on file is 25.35. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.81. Measured against sales, the shares trade at 14.52 times revenue. On price-to-sales that is 4.85% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +60.91%. Across 10 years the annualized return works out at +35.60%. Beta against the wider market is reported at 0.45. Daily returns over the trailing 10 years annualize to a volatility of 67.78%.

Growth & Income

The record shows no dividend for CORT.

So far in 2026 the price is +220.75%. Across the complete calendar years on file, 2017 returned +148.76% and 2025 returned −30.94%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Corcept Therapeutics Incorporated (CORT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Corcept Therapeutics Incorporated CORT $12.07B 248.0
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Corcept Therapeutics Incorporated trades at a P/E of 248.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Visit website →